Johnson & Johnson's Q3 2023: $21.3B Rise In Sales, 'Sharpened Focus' On Innovation & Biotech Solutions
Johnson & Johnson's Q3 2023: $21.3B Rise In Sales, 'Sharpened Focus' On Innovation & Biotech Solutions
Healthcare company Johnson & Johnson (J&J) (NYSE:JNJ) shared its financial outcomes for the third quarter of 2023, reflecting:
醫療保健公司強生(強生)(紐約證券交易所股票代碼：JNJ)分享了2023年第三季度，反映：
-
Total reported sales of $21,351 million, a 6.8% increase compared to the same period in 2022. Of which U.S. sales totaled $11,996 million (11.1% increase from 2022's comparable period), and the rest of the world $9,355 million (1.6% increase from 2022's same period.)
-
In terms of segments, reported sales owe 65.0% to Innovate Medicine ($13,893 million, a 5.1% growth from 2022's same period); and 34.9% to MedTech ($7,458 million, a 10.0% growth from 2022's same period.)
-
In terms of psychedelics, these numbers involve Spratavo (S-ketamine) sales for a total of $154 million in the U.S., a 75% increase compared to 2022's same quarter and $29 million in the rest of the world.
-
報告的總銷售額213.51億美元，增長6.8%與2022年同期相比。其中美國銷售額總計119.96億美元(比2022年‘S同期增長11.1%)，世界其他地區為93.55億美元(比2022年’S同期增長1.6%)。
-
在細分市場方面，報告創新醫學銷售額欠65.0%(138.93億美元，較2022年同期的S增長5.1%)；MedTech佔34.9%(74.58億美元，較2022年S的同期增長10.0%。)
-
在迷幻藥方面，這些數位涉及斯普拉塔沃(S-氯胺酮)銷售美國的總票房收入為1.54億美元，比《S》2022年同季度的票房收入增長了75%，全球其他地區的票房收入為2,900萬美元。
See Also: Sales Of Johnson & Johnson Esketamine Drug Spravato Rise Nearly 100% Year Over Year
另見：強生的埃斯氯胺酮藥物斯普拉瓦託的銷售額同比增長近100%
-
Net earnings of $4,309 million, slightly behind 2022's comparable period of $4,310 million. Yet earnings per share (diluted) increased 4.3% from period to period from $1.62 in 2022 to $1.69 in 2023.
-
The cost of products sold was $6,606 million vs. $6,172 million in the same 2022 period.
-
R&D expenses totaled $3,447 million, vs. $3,485 million in the same 2022 period.
-
Selling, marketing and administrative expenses for a total $5,400 million, an 8% increase from 2022 ($4,975 million.)
-
淨收益43.09億美元略低於2022年S的43.1億美元。然而，每股收益(稀釋後)從2022年的1.62美元增長到2023年的1.69美元，增幅為4.3%。
-
銷售產品的成本為66.06億美元，而2022年同期為61.72億美元。
-
研發費用總額為34.47億美元，而2022年同期為34.85億美元。
-
銷售、營銷和管理費用總計54億美元，比2022年(49.75億美元)增長了8%。
The quarter also saw a one-time, non-cash gain of around $21 billion, related to the final separation of J&J's consumer health business and considered as part of its discontinued operations.
該季度還出現了一次性非現金收益約為210億美元，與強生消費者健康業務的最終分離有關，並被視為其非持續業務的一部分。
Pipeline, Programs & IP
流水線、程式和IP
On the regulatory front, J&J received several treatment approvals from the FDA and the European Commission (2). Additionally, it submitted two applications to the European Medicines Agency, and another supplemental New Drug Application (NDA) to the FDA.
論監管戰線，強生獲得了來自林業局以及歐盟委員會(2)。此外，它還向委員會提交了兩份申請歐洲藥品管理局，以及向FDA提交的另一項補充新藥申請(NDA)。
The company also released data on several different development programs, around the multi-targeting bispecific monoclonal antibody RYBREVANT. It as launched the OPTRELL catheter for the mapping of complex cardiac arrhythmias.
該公司還公佈了圍繞多靶點雙特異性單抗RYBREVANT的幾個不同開發專案的數據。它作為推出的OPTREL導管用於複雜心律不整的標測。
CEO and board chairman Joaquin Duato said the quarter's "strong results" along with "significant pipeline advances" altogether provide "a solid foundation for future sustained growth."
首席執行官兼董事會主席華金·杜阿託該公司表示，該季度的“強勁業績”和“重大進展”共同為“未來的持續增長奠定了堅實的基礎”。
"With a sharpened focus on Innovative Medicine and MedTech solutions, Johnson & Johnson is innovating across the spectrum of healthcare and is poised to deliver the medical breakthroughs of tomorrow," Duato added.
杜阿託補充說：“隨著對創新醫學和醫療技術解決方案的更加關注，強生正在醫療保健的各個領域進行創新，並準備實現明天的醫療突破。”
See full financial results, business collaborations and earnings presentation here.
點擊此處查看完整的財務結果、業務協作和收益演示。
Photo: Benzinga edit with photo by Commons and Pexels.
圖片來源：Benzinga編輯，照片由Commons和Pexels提供。